Evidence map›Paper›PMID 41273653›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Development of a Gene Therapy with Lentiviral Vectors for Spinocerebellar Ataxias.

Tiago Moreira-Gomes, Clévio Nóbrega

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tiago Moreira-GomesABC-Ri, Algarve Biomedical Center Research Institute, Faro, Portugal.
Clévio NóbregaABC-Ri, Algarve Biomedical Center Research Institute, Faro, Portugal. cdnobrega@ualg.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among viral vectors, lentiviral vectors allow an efficient delivery of nucleic acid to the target cells due to its ability of gene integration into host genome and broad tropism. In this sense, this tool demonstrated to be very promising in genetic disorders, such as polyglutamine spinocerebellar ataxias. Therefore, we describe a protocol that explains in detail the production, purification, and injection of lentiviral vectors in a spinocerebellar ataxia mouse model.

Indexed as

Genetic TherapyGenetic VectorsLentivirusSpinocerebellar AtaxiasAnimalsDisease Models, AnimalHumansMiceTransduction, GeneticGene therapyHEK 293 T cellsLentiviral vectorsProduction of lentiviral vectorsSpinocerebellar ataxia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.